Atrial natriuretic factor (ANF) is a potent bronchodilator in asthma

J Allergy Clin Immunol. 1990 Sep;86(3 Pt 1):321-4. doi: 10.1016/s0091-6749(05)80094-6.

Abstract

The bronchodilating effects of atrial natriuretic factor (ANF) were compared to effects of salbutamol in a double-blind, placebo-controlled, crossover study in eight subjects with asthma and with airflow limitation. ANF was infused intravenously (0.1 microgram/kg/min during 30 minutes) and caused a short-lasting significant (p less than 0.012) bronchodilation in all patients similar in intensity to intravenous salbutamol (0.13 microgram/kg/min). The duration of the effect of the beta 2-agonist, however, was longer. No severe side effects were noted with ANF infusion. ANF may play a role in the modulation of the bronchial tone in humans, but its usefulness in the treatment of asthma remains to be determined.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Asthma / drug therapy*
  • Asthma / physiopathology
  • Atrial Natriuretic Factor / blood
  • Atrial Natriuretic Factor / therapeutic use*
  • Double-Blind Method
  • Forced Expiratory Volume
  • Humans

Substances

  • Atrial Natriuretic Factor